Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists

Clinical and Experimental Pharmacology and Physiology

Volumn 23, Issue SUPPL. 3, 1996, Pages

  Campbell, Duncan J ^a  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Angiotensin; Angiotensin receptor; Angiotensin receptor antagonist; Angiotensin converting enzyme inhibitor; Angiotensin converting enzymes

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN ANTAGONIST; ANGIOTENSIN RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; LOSARTAN; PERINDOPRIL; ANGIOTENSIN II; RENIN;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; CONFERENCE PAPER; DOSE RESPONSE; DRUG MECHANISM; HORMONE RELEASE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; RECEPTOR BINDING; BLOOD; BLOOD PRESSURE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; HYPERTENSION; KIDNEY; METABOLISM; TISSUE DISTRIBUTION;

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; HUMANS; RECEPTOR, ANGIOTENSIN, TYPE 1; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTENSION; KIDNEY; RECEPTORS, ANGIOTENSIN; RENIN; TISSUE DISTRIBUTION;

EID: 0029768429     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (68)

1. Hansson L, Dahlöf B, Himmelmann A, Svensson A. Angiotensin-converting enzyme inhibitors in the treatment of essential hypertension. In: Robertson JIS, Nicholls MG (eds). The Renin-Angiotensin System. Gower Medical Publishing, London. 1993; Ch. 91.
2. Crozier IG, Ikram H, Nicholls MG. Angiotensin-converting enzyme inhibitors in the treatment of heart failure. In: Robertson JIS, Nicholls MG (eds). The Renin-Angiotensin System. Gower Medical Publishing, London. 1993; Ch. 93.
3. Timmermans PBMWM, Wong PC, Chiu AT et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 1993; 45: 205-51.
4. Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J. Hypertens. 1994; 12 (Suppl. 2): S37-42.
5. Dickstein K, Gottlieb S, Fleck E et al. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. J. Hypertens. 1994; 12 (Suppl. 2): S31-5.
6. Crozier I, Ikram H, Awan N et al. Losartan in heart failure: Hemodynamic effects and tolerability. Circulation 1995; 91: 691-7.
7. Crozier IG, Richards AM, Ikram H, Nicholls MG. The renin-angiotensin system, ACE inhibitors, and cardiac structure. In: Robertson JIS, Nicholls MG (eds). The Renin-Angiotensin System. Gower Medical Publishing, London. 1993; Ch. 94.
8. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N. Engl. J. Med. 1988; 319: 80-6.
9. Lonn EM, Yusuf S, Jha P et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90: 2056-69.
10. Greenwald L, Becker RC. Expanding the paradigm of the renin-angiotensin system and angiotensin-converting enzyme inhibitors. Am. Heart J. 1994; 128: 997-1009.
11. Powell JS, Clozel J-P, Müller RKM et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245: 186-8.
12. Fennessy PA, Campbell JH, Campbell GR. Perindopril inhibits both the development of atherosclerosis in the cholesterol-fed rabbit and lipoprotein binding to smooth muscle cells in culture. Atherosclerosis 1994; 106: 29-41.
13. Unger T, Gohlke P, Gruber M-G. Converting enzyme inhibitors. In: Ganten D, Mulrow PJ (eds). Pharmacology of Antihypertensive Therapeutics. Handbook of Experimental Pharmacology, vol. 93. Springer-Verlag, Berlin. 1990; 377-481.
14. Campbell DJ, Kladis A, Duncan A-M. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23: 439-49.
15. Campbell DJ, Kladis A, Valentijn AJ. Effects of losartan on angiotensin and bradykinin peptides, and angiotensin converting enzyme. J. Cardiovasc. Pharmacol. 1995; 26: 233-40.
16. Ehlers MRW, Riordan JF. Angiotensin-converting enzyme: Biochemistry and molecular biology. In: Laragh JH, Brenner BM (eds). Hypertension: Pathophysiology, Diagnosis, and Management. Raven Press, New York. 1990; 1217-31.
17. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev. 1995; 47: 25-49.
18. Nussberger J, Brunner DB, Waeber B, Brunner HR. Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma. Hypertension 1986; 8: 476-82.
19. Nussberger J, Brunner DB, Waeber B, Brunner HR. True versus immunoreactive angiotensin II in human plasma. Hypertension 1985; 7 (Suppl. I): I1-7.
20. Nussberger J, Brunner DB, Waeber B, Brunner HR. In vitro renin inhibition to prevent generation of angiotensins during determination of angiotensin I and II. Life Sci. 1988; 42: 1683-8.
21. Juillerat L, Nussberger J, Ménard J et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990; 16: 564-72.
22. Mento PF, Wilkes BM. Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension 1987; 9 (Suppl. III): III42-8.
23. Kawamura M, Imanashi M, Matsushima Y, Ito K, Hiramori K. Circulating angiotensin II levels under repeated administration of lisinopril in normal subjects. Clin. Exp. Pharmacol. Physiol. 1992; 19: 547-53.
24. Gadsboll N, Damkjaer Nielsen M, Giese J, Leth A, Lonborg-Jensen H. Diurnal monitoring of blood pressure and the renin-angiotensin system in hypertensive patients on long-term angiotensin-converting enzyme inhibition. J. Hypertens. 1990; 8: 733-40.
25. Mooser V, Nussberger J, Juillerat L et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J. Cardiovasc. Pharmacol. 1990; 15: 276-82.
26. Berka JLA, Alcorn D, Coghlan JP et al. Granular juxtaglomerular cells and prorenin synthesis in mice treated with enalapril. J. Hypertens. 1990; 8: 229-38.
27. Campbell DJ, Lawrence AC, Towrie A, Kladis A, Valentijn AJ. Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension 1991; 18: 763-73.
28. Allan DR, McKnight JA, Kifor I, Coletti CM, Hollenberg NK. Converting enzyme inhibition and renal tissue angiotensin II in the rat. Hypertension 1994; 24: 516-22.
29. Campbell DJ, Duncan A-M, Kladis A, Harrap SB. Converting enzyme inhibition and its withdrawal in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 1995; 26: 426-36.
30. Guyton AC, Hall JE, Coleman TG, Manning RD Jr, Norman RA Jr. The dominant role of the kidneys in long-term arterial pressure regulation in normal and hypertensive states. In: Laragh JH, Brenner BM (eds). Hypertension: Pathophysiology, Diagnosis, and Management, 2nd edn. Raven Press Ltd, New York. 1995; 1311-26.
31. Hall JE, Guyton AC, Brands MW. Control of sodium excretion and arterial pressure by intrarenal mechanisms and the renin-angiotensin system. In: Laragh JH, Brenner BM (eds). Hypertension: Pathophysiology, Diagnosis, and Management, 2nd edn. Raven Press Ltd, New York. 1995; 1451-75.
32. Hollenberg NK, Meggs LG, Williams GH, Katz J, Garnic JD, Harrington DP. Sodium intake and renal responses to captopril in normal man and in essential hypertension. Kidney Int. 1981; 20: 240-5.
33. Dzau VJ, Colucci WS, Williams GH, Curfman G, Meggs L, Hollenberg NK. Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. N. Engl. J. Med. 1980; 302: 1373-9.
34. Unger T, Gohlke P, Ganten D, Lang RE. Converting enzyme inhibitors and their effects on the renin-angiotensin system of the blood vessel wall. J. Cardiovasc. Pharmacol. 1989; 13 (Suppl. 3): S8-16.
35. Unger T, Ganten D, Lang RE, Scholkens BA. Persistent tissue converting enzyme inhibition following chronic treatment with Hoe498 and MK421 in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 1985; 7: 36-41.
36. Naftilan AJ. Role of the tissue renin-angiotensin system in vascular remodeling and smooth muscle cell growth. Curr. Opin. Nephrol. Hypertens. 1994; 3: 218-27.
37. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J. Hypertens. 1984; 2: 277-84.
38. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ. Res. 1990; 66: 883-90.
39. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J. Biol. Chem. 1990; 265: 22 348-57.
40. Campbell DJ. Metabolism of prorenin, renin, angiotensinogen, and the angiotensins by tissues. In: Robertson JIS, Nicholls MG (eds). The Renin-Angiotensin System. Gower Medical Publishing, London. 1993; Ch. 23.
41. Aiken JW, Vane JR. The renin-angiotensin system: inhibition of converting enzyme in isolated tissues. Nature 1970; 228: 30-4.
42. Chandrasekharan UM, Sanker S, Glynias MJ, Karnik SS, Husain A. Angiotensin II-forming activity in a reconstructed ancestral chymase. Science 1996; 271: 502-5.
43. Boomsma F, De Bruyn JHB, Derkx FHM, Schalekamp MADH. Opposite effects of captopril on angiotensin I-converting enzyme 'activity' and 'concentration'; relation between enzyme inhibition and long-term blood pressure response. Clin. Sci. 1981; 60: 491-8.
44. Fyhrquist F, Gronhagen-Riska C, Hortling L, Forslund T, Tikkanen I. Regulation of angiotensin converting enzyme. J. Hypertens. 1983; 1 (Suppl. 1): 25-30.
45. Lawrence AC, Evin G, Kladis A, Campbell DJ. An alternative strategy for the radioimmunoassay of angiotensin peptides using amino-terminal-directed antisera: Measurement of eight angiotensin peptides in human plasma. J. Hypertens. 1990; 8: 715-24.
46. Asmar RG, Pannier BM, Santoni JP et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 1988; 78: 941-50.
47. Benetos A, Santoni JP, Safar ME. Vascular effects of intravenous infusion of the angiotensin converting enzyme inhibitor perindoprilat. J. Hypertens. 1990; 8: 819-26.
48. Campbell DJ, Ziogas J, Kladis A. Metabolism of tetradecapeptide, angiotensinogen, and angiotensin I and II by isolated perfused rat hindlimbs. Clin. Exp. Pharmacol. Physiol. 1990; 17: 335-50.
49. Hilgers KF, Kuczera M, Wilhelm MJ et al. Angiotensin formation in the isolated rat hindlimb. J Hypertens. 1989; 7: 789-98.
50. Foult J-M, Tavolaro O, Antony I, Nitenberg A. Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: Assessment by a bilateral intracoronary infusion technique. Circulation 1988; 77: 337-44.
51. Haber HL, Powers ER, Gimple LW et al. Intracoronary angiotensin-converting enzyme inhibition improves diastolic function in patients with hypertensive left ventricular hypertrophy. Circulation 1994; 89: 2616-25.
52. Friedrich SP, Lorell BH, Rousseau MF et al. Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis. Circulation 1994; 90: 2761-71.
53. Zisman LS, Abraham WT, Meixell GE et al. Angiotensin II formation in the intact human heart: Predominance of the angiotensin-converting enzyme pathway. J. Clin. Invest. 1995; 96: 1490-8.
54. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: A meta-analysis of 109 treatment studies. Am. J. Hypertens. 1992; 5: 95-110.
55. Chen C-H, Ting C-T, Lin S-J et al. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension 1995; 25: 1034-41.
56. Levy BI, Benessiano J, Poitevin P, Safar ME. Endothelium-dependent mechanical properties of the carotid artery in WKY and SHR: Role of angiotensin converting enzyme inhibition. Circ. Res. 1990; 66: 321-8.
57. Bunkenburg B, Schnell C, Baum H-P, Cumin F, Wood JM. Prolonged angiotensin II antagonism in spontaneously hypertensive rats. Hemodynamic and biochemical consequences. Hypertension 1991; 18: 278-88.
58. Christen Y, Waeber B, Nussberger J et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: Inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991; 83: 1333-42.
59. Burnier M, Hagman M, Nussberger J et al. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995; 25: 602-9.
60. Burnier M, Rutschmann B, Nussberger J et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993; 22: 339-47.
61. Cockcroft JR, Sciberras DG, Goldberg MR, Ritter JM. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J. Cardiovasc. Pharmacol. 1993; 22: 579-84.
62. Nelson EB, Harm SC, Goldberg M, Shahinfar S, Goldberg A, Sweet CS. Clinical profile of the first angiotensin II (AT-I specific) receptor antagonists. In: Laragh JH, Brenner BM (eds). Hypertension: Pathophysiology, Diagnosis, and Management, 2nd edn. Raven Press Ltd, New York. 1995; 2895-916.
63. Erley CM, Bader B, Scheu M, Wolf S, Braun N, Risler T. Renal hemodynamics in essential hypertensives treated with losartan. Clin. Nephrol. 1995; 43 (Suppl. 1): S8-11.
64. 1 angiotensin II receptors in rat brain, kidney and adrenals demonstrated by in vitro autoradiography. Clin. Exp. Pharmacol. Physiol. 1994; 21: 557-67.
65. Wood JM, Schnell CR, Levens NR. Kidney is an important target for the antihypertensive action of an angiotensin II receptor antagonist in spontaneously hypertensive rats. Hypertension 1993; 21: 1056-61.
66. Burnier M, Pechère-Bertschi A, Nussberger J, Waeber B, Brunner HR. Studies of the renal effects of angiotensin II receptor blockade: The confounding factor of acute water loading on the action of vasoactive systems. Am. J. Kidney Dis. 1995; 26: 108-15.
67. 2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J. Clin. Invest. 1995; 95: 651-7.
68. Azizi M, Chatellier G, Guyene T-T, Murieta-Geoffroy D, Mènard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995; 92: 825-34.